Activated leukocytes are believed to be involved in the pathogenesis and progression of atherosclerotic vascular disease and its consequences. In a 4-year observational follow-up study, we investigated whether markers for systemic leukocyte activation (leukocyte-derived inflammatory mediators) were related to cardiovascular mortality after cerebrovascular ischemia. Using enzyme-linked immunosorbent assays, we measured the plasma levels of soluble tumor necrosis factor receptor protein-1 (sTNFR-1), neutrophil gelatinase-associated lipocalin (NGAL) and neutrophil protease-4 (NP4) in 144 patients (90 stroke, 54 transient ischemic attack) 1–3 days after cerebral ischemia. During the 4 years of follow-up, 42 (29%) of the 144 patients died; 38 of cardiovascular causes and 4 of other causes. Patients with evidence of higher leukocyte activation (n = 47) had a higher 4-year cardiovascular mortality rate than those without evidence of leukocyte activation (n = 97; p < 0.005). Logistic regression analysis with age, sex and other significant predictors as covariates showed higher plasma levels of sTNFR1 and NGAL both to be significant independent predictors of cardiovascular mortality, the respective odds ratio, 95% confidence intervals, and p values being 2.0, 1.2–3.4, p < 0.01, and 3.6, 1.2–10.5, p = 0.02, respectively. We concluded that in patients with acute cerebral ischemia, plasma markers of leukocyte activation were significant predictors of long-term cardiovascular mortality. This may indicate an important role of activated leukocytes in the progression of these diseases.

1.
Friedman GD, Klatsky AL, Siegelaub AB: The leukocyte count as a predictor of myocardial infarction. N Engl J Med 1974;290:1275–1278.
2.
Prentice RL, Szatrowski TP, Kato H, Mason MW: Leukocyte counts and cerebrovascular disease. J Chronic Dis 1982;35:703–714.
3.
Shlant RC, Forman S, Stamler V, Canner PL: The natural history of coronary heart disease: Prognostic factors after recovery from myocardial infarction in 2,789 men. Circulation 1982;66:401–408.
4.
Lowe GD, Machado SG, Krol WF, Barton BA, Forbes CD: White blood cell count and hematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Haemost 1985;54:700–703.
5.
Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 1986;83:4533–4537.
6.
Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr: Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984;160:618–623.
7.
Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994;76:301–314.
8.
Del Maschio A, Evangelista V, Rajtar G, Chen ZM, Cerletti C, De Gaetano G: Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents. Am J Physiol 1990;258(3 pt 2):H870–H879.
9.
Nash GB: Adhesion between neutrophil and platelets: A modulator of thrombotic and inflammatory events. Thromb Res 1994;74:S3–S11.
10.
Østerud B: A global view of the role of monocytes and platelets in atherogenesis. Thromb Res 1997;85:1–22.
11.
van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 1990;76:2520–2526.
12.
van der Wal A, Becker AE, van der Loos CM, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammation process irrespective of the dominant plaque morphology. Circulation 1994;89:36–44.
13.
Mehta JL, Nichols WW, Mehta P: Neutrophils as potential participants in acute myocardial ischemia: Relevance to reperfusion. J Am Coll Cardiol 1988;11:1309–1316.
14.
del Zoppo GJ, Schmid-Schönbein GW, Mori E, Copeland BR, Chang CM: Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991;22:1276–1283.
15.
Axelsson L, Bergenfeldt M, Ohlsson K: Studies of the release and turnover of a human lipocalin. Scand J Clin Lab Invest 1995;55:577–588.
16.
Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425–10432.
17.
Lundberg E, Bergenfeldt M, Ohlsson K: Release of immunoreactive human neutrophil proteinase 4, normally and in peritonitis. Scand J Clin Lab Invest 1991;51:23–29.
18.
Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN: Human tumor necrosis factor. Production, purification and characterization. J Biol Chem 1985;260:2345–2354.
19.
Peetre C, Thysell H, Grubb A, Olsson I: A tumor necrosis factor binding protein is present in human biological fluids. Eur J Haematol 1988;41:414–419.
20.
Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D: Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995;54:1–8.
21.
Engelberts I, Moller A, Schoen GI, van-der-Linden CJ, Buurman WA: Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res 1991;10:69–76.
22.
Elneihoum AM, Falke P, Axelsson L, Lundberg E, Lindgärde F, Ohlsson K: Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke 1996;27:1734–1738.
23.
Anwaar I, Gottsäter A, Ohlsson K, Lindgärde F, Mattaisson I: Increasing levels of leukocyte derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia. Cerebrovasc Dis 1998;8:310–317.
24.
Beamer NB, Coull BM, Clork WM, Briley DP, Wynn DO, Sexton G: Persistent inflammatory response in stroke survivors. Neurology 1998;50:1722–1728.
25.
Bonita R: Epidemiology of stroke. Lancet 1992;339:342–347.
26.
Ohlsson K, Linder C, Lundberg E, Axelsson L: Release of cytokines and proteases from human peripheral blood mononuclear and polymorphonuclear cells following phagocytosis and LPS stimulation. Scand J Clin Lab Invest 1996;56:461–470.
27.
Falke P, Jerntop P, Pessah-Rasmussen H: Differences in cardiac disease prevalence and in blood variables between major and minor stroke patients. Int Angiol 1993;12:5–8.
28.
Burr ML, Holliday RM, Fehily AM, Whitehead PJ: Haematological prognostic indices after myocardial infarction: Evidence from the Diet and Reinfarction. Trial (DART). Eur Heart J 1992;13:166–170.
29.
Liuzzo G, Biascucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: Prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417–424.
30.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and risk for cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–979.
31.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425–428.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.